The financial barrier to developing antibiotics? No big payday for drug companies

As current antibiotics begin to lose their punch, there’s an economic reality putting a damper on development. Since every use of an antibiotic drives resistance, and doctors are reluctant to use a drug until there’s no alternative, why would a drug company spend a fortune? Economics correspondent Paul Solman and science correspondent Miles O’Brien continue their look at the hunt for new drugs.